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Abstract Bothintermsofmorbidityandmortality, the therapeutic andorganizationalmanagementof asthmapose a
considerable andcontinuingchallengetohealthcare delivery.One elementin attempts tomeetthis challengeis therecog-
nition of appropriate outcome measures to assess progress in tackling the burden of this disease.This study therefore
aimed to assess pragmatically the e¡ectiveness of a revised asthma morbidity index in identifying varying patterns of
morbidityin U.K. generalpractices.Apostal surveywas conductedof 2762 patientsbelievedtohave orhavehadasthma
fromthelists of12 generalpracticeswithinthe EdenValleyin Cumbria, usinga questionnairewhichcombinedtherevised
Jonesmorbidity index with questions on age, medication and perception of current asthma.Prescribing datawere also
recovered for11ofthepractices for thequarterwithinwhichthepostalsurveywasconducted.Responseswereobtained
from2123 subjects (77%), ofwhom1474 (70%) believedthemselvestobecurrentlyasthmatic.Inthisgroup,18% reported
low morbidity, 34% mediummorbidity and 48% high morbidity. Age and inhaled steroid use were both positively and
signi¢cantly associatedwithhighmorbidity.Those taking inhaled steroidswere1?4 timesmore likely to reporthighmor-
bidity thanthosenottakingsteroids.Theprescribedcorticosteroid/bronchodilatorratio forcostwasbothnegativelyand
signi¢cantlyassociatedwithhighmorbidity.Therevisedmorbidityindexis a simpletoolofuseinthe surveillanceof asthma
in primary care. It identi¢es spectra of morbidity which vary between practices, which may be of use in assessing the
qualityof asthma care provided inthe community.r2001Harcourt Publishers Ltd
doi:10.1053/rmed.2001.1184, available online athttp://www.idealibrary.comon
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The therapeutic and organizationalmanagement of asth-
ma poses a considerable and continuing challenge to
healthcare delivery.One element in attempts tomeet this
challenge is the recognition of pragmatic outcome mea-
sures to assess progress in tackling theburden of asthma.
The original Jonesmorbidity index, based on the simple
yes/no answers to three straight-forward, clinically
relevant questions and producing categories of low,Received13 March 2000 and accepted in revised form13 July 2001.
Correspondence shouldbe addressed to:Dr K.P. Jones,Department of
Primary Health Care,University of Newcastle,Newcastle NE2 4HH,
U.K.medium and high morbidity signi¢cantly associated with
lung function (1,2), has been much used in U.K. general
practice and found useful for one-o¡ enquiries but
required the inclusion of a temporal quali¢er to enable
repeated testing (see Fig. 1 for revised version). Evidence
of the susceptibility to change of the revised index in the
setting of a nurse-run asthma clinic in primary careFand
indeed of the e¡ectiveness of such careF has already
been established (3). Data on the relationship of the re-
vised index to lung function indicate a stronger relation-
ship than with the original version and the predictive
validity of the instrument has been demonstrated (4).
Thus, the index has been shown to be useful despite in-
cluding a question about work or school absence which
does not refer to all thosewith asthma.
FIG. 1 The Revised Jones Morbidity Index.
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outcomes and utility, but clearly a further possibility is
the aggregation of data across communities such as the
registered lists of general practitioners for comparative
purposes.Wehave conducted a further evaluation of the
revised form of the Jones morbidity index using postal
questionnaires in the setting of routine general practice
to address itsuse in identifyingwhethermorbidityvaried
between practices.
METHODS
The study was conducted in the12 practices which form
the Eden Valley General Practice Research Group situ-
ated in the eastern part of Cumbria in north-west Eng-
land. All but one of these practices come under the aegis
of the North Cumbria Health Authority, Carlisle, U.K.,
with the other reporting to Durham. Each practice was
asked to identify all those subjects of any age registered
on their lists with asthma past or present. The precise
methodof so doingwas deliberately left to each practice,
since our purpose was to use the already validated mor-
bidity index pragmatically in routine practice. A simple,
singlepage questionnairewasmailed to each subjectwith
onereminder to non-respondents after 6weeks.Mailings
concerning children were addressed to their parents or
guardians. The questionnaire comprised six items: (1) do
you think you have asthma now?; (2)^(4) the three ques-
tions of the revised Jones morbidity index (see Fig.1); (5)
please list any treatment you are currently taking for
asthma; and (6) please tick your age (0^4, 5^15,
16^40, 41^65, 4 65years). Those subjects answering
‘yes’ to question1were regarded as a subsetwith‘current
asthma’, while the whole data set was labelled as ‘diag-
nosed asthma’.
The questionnaires were returned to the Cumbria
Primary Care E¡ectiveness Group in Carlisle and en-
tered onto Microsoft Excel spreadsheets. These datawere analysed using STATAV4. Data on list size at the
time of the survey were returned by the practices and
with their permission data on corticosteroid/bronchodi-
lator cost ratios were obtained for the same quarter as
the survey from the Director of Primary Care at the
North Cumbria Health Authority. Logistic regression
was used on the combined dataset to investigate the ef-
fect of age and inhaled steroids on morbidity. Possible
practice di¡erences were not allowed for in the model.
Since one clinical use of the index is to focus care on
those reporting high morbidity, for analytic purposes
morbidity was split into two categories: high and med-
ium/low. Spearman’s rank correlation coe⁄cient was
used to investigate an association between the percen-
tage of patients in a practice reporting high morbidity
and the practice corticosteroid/bronchodilator cost
ratio and also associations between prevalence of
asthma and the proportions of those reporting high
morbidity. This latter analysis was intended to address
whether rising prevalence was accounted for by more
mild cases.
RESULTS
The 12 practices had a combined list size of 47 752, of
whom 2762 (5?8%) were regarded as having or having
had asthma. Fully completed responses were obtained
from 2123 subjects (77%), of whom1474 believed them-
selves to be currently asthmatic (70% of respondents,
3?1% of the whole population). Response rates in indivi-
dual practices varied from 69% to 85% (seeTable 1). The
practice list sizes varied from1995 to13 000, with amed-
ian of 3000.Thepercentages of subjectswith asthmavar-
ied from 4?0 to 10?1 (Table 1), and of those with current
asthma from 2?2 to 5?0 (Table 2).
Overall, 714 subjects (34%) reported low morbidity,
617 (29%) reported medium morbidity and 792 (37%)
high morbidity. Forty-seven records were not complete.
The percentages of highmorbidity variedbetween prac-
tices from 30% to 58% (Table1).There was a very strong
negative relationship between prevalence of diagnosed
asthma and proportion of those with diagnosed asthma
reporting high morbidity (Spearman correlation=
ÿ 0?78, P=0?003). There was no signi¢cant relationship
between the prevalence of current asthma and the pro-
portion of those with current asthma reporting high
morbidity (Spearman correlation=ÿ0?42,P=0?18).
Since those perceiving themselves to be currently
asthmatic were also much more likely to report high
morbidity (47% vs. 12%, chi-squared 549, 2 df, Po0.001)
and to be taking inhaled steroids (65% vs. 20%, chi-
squared 819, 2 df,Po0?001), further analysis is restricted
to this group alone. The breakdown of morbidity for
those currently asthmatic was 271 (18%) low, 503 (34%)
medium and 700 (47%) high; signi¢cant variations existed
TABLE 1 Morbiditybreakdown for allpatientswith asthma
Morbidity (% of practice asthmatics)
Practice1 Prevalence of
asthma (%)
Response rate to
questionnaires (%)
Low Medium High Total
1 5?8 76 207 (36) 154 (27) 214 (37) 575
2 5?9 79 37 (40) 28 (30) 28 (30) 93
3 6?3 83 89 (39) 69 (30) 72 (31) 230
4 6?1 70 71 (32) 69 (31) 84 (38) 224
5 5?0 69 54 (36) 40 (27) 54 (36) 148
6 4?8 85 28 (21) 45 (34) 58 (44) 131
7 4?3 78 11 (14) 21 (27) 45 (58) 77
8 4?0 80 19 (22) 28 (33) 39 (45) 86
9 7?4 75 60 (37) 54 (33) 50 (30) 164
10 4?5 80 28 (29) 24 (25) 45 (46) 97
11 10?1 83 63 (38) 46 (28) 58 (35) 167
12 5?3 82 47 (36) 39 (30) 45 (34) 131
Total mean 5?8 mean 77 714 (34) 617 (29) 792 (37) 2123
Pearson chi-squared 50, 22 df, P=0?001.
NB1:Rowpercentages do not all addup exactly to100 because of rounding to the nearest integer.
NB 2:Prevalences onlyof asthma givento preserve anonymity.
TABLE 2 Morbiditybreakdown forcurrent asthmatics only
Morbidity (% of practice current asthmatics)
Practice Low Medium High Total (% of practice list size)
1 94 (23) 127 (31) 193 (47) 414 (4?2)
2 16 (25) 24 (38) 23 (37) 63 (4?1)
3 36 (24) 53 (36) 60 (40) 149 (3?5)
4 25 (16) 61 (38) 75 (47) 161 (5?3)
5 11 (12) 34 (36) 49 (52) 94 (3?1)
6 15 (14) 39 (38) 50 (48) 104 (5?.2)
7 5 (8) 16 (27) 39 (65) 60 (2?9)
8 8 (12) 23 (35) 35 (53) 66 (2?8)
9 22 (22) 35 (36) 41 (42) 98 (4?8)
10 9 (13) 19 (28) 40 (59) 68 (4?3)
11 10 (10) 37 (37) 53 (53) 100 (6?0)
12 20 (21) 35 (36) 42 (43) 97 (3?9)
Total 271 (18) 503 (34) 700 (47) 1474 (4?2)
Pearson chi-squared=40, 22 df, P=0?011.
NB:Rowpercentages do not all addup exactly to100 because of rounding to the nearest integer.
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22 df, P=0?011). This group also had a higher proportion
of old people and fewer young children than those not
currently asthmatic.There were signi¢cant variations in
the age categories between practices (data not shown).
The mean inhaled steroid use in the currently asthmatic
group was 65%, but rates varied by practice from 55%
to 75%.
The logistic regression analysis showed that age and
inhaled steroid use are both associated positively with
high morbidity. Those taking inhaled steroids were 1?4times more likely to report high morbidity than those
not (95% con¢dence interval of odds ratio 1?1^1?8,
P=0?001). Those in the 41^65 years age group were 1?3
timesmore likely to report high morbidity than those in
the 0^40 years age group (95% con¢dence interval of
odds ratio 1?0^1?7, P=0?03). Those in the over 65 age
group were1?6 timesmore likely to report highmorbid-
ity than those in the 0^40 years age group (95% con¢-
dence interval of odds ratio 1?2^2?1, P=0?001).The e¡ect
of age and use of steroids on high morbidity is shown
inTable 3. Despite age and use of inhaled steroids both
TABLE 3. Highmorbidityby age and inhaled sterioduse
Percentage of patients reportinghighmorbidity
Inhaled steriods Age (years)
0^40 41^65 465 Total
Yes 37% 43% 54% 41%
No 47% 54% 56% 51%
Total 43% 50% 56% 47%
FIG. 2. Associationbetweenpercentage ofcurrent asthmaticswithhighmorbidityandcorticosteroid/bronchodilatorratio forcost.
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morbidity, these variables accounted for only 1% of the
variability in high morbidity. It is therefore unlikely that
di¡erences in the age structure and the prescribing of
inhaled steroids between practices could account for
the large variability seen between practices in terms of
highmorbidity.
Themean corticosteroid/bronchodilator ratio by cost
was 1?5 (range 0?69^2?4). A plot of these ratios against
observedhighmorbidity is shown in Fig. 2.The trend visi-
blewas signi¢cant (Spearman’s rhoÿ0?73,P=0?01).
DISCUSSION
Postal use of themorbidity indexdoes produce estimates
of high morbidity which vary signi¢cantly between prac-
tices to an extent not fully explainedbydi¡erences in age,
use of inhaled steroids or the prevalence of diagnosed
asthma. Furthermore, the use of number of people withasthma on preventative treatmentFa key component of
required annual reports from practicesFhas been
shown by our data to be potentially misleading (being
positively associatedwith highmorbidity).However, rising
prevalence of diagnosedasthmadoes appear tobe inpart
explainedby greater numbers ofmoremild cases.
Some cautions in interpreting these data are neces-
sary.Firstly, methods of identifying the asthmatic cohort
may wellhavevaried inwayswhich couldhave in£uenced
the makeup of the sample. It is for this reason that our
analysis hasbeenrestricted to thosepatientswhoregard
themselves as currently asthmatic sincewe believe these
to be a more homogeneous group of patients than those
selected as being asthmatics by the di¡erent practices.
The potential signi¢cance of this possibility is likely to
be small, but this can only be speculation. Secondly, the
self-reporteddata onuse of inhaled steroidswas notver-
i¢ed against individual prescription records. Thirdly, the
corticosteroid/bronchodilator ratios obtained refer to
all the patients in the practices using these drugs (asth-
1010 RESPIRATORYMEDICINEmatic responders and non-responders alike, those with
chronic obstructive pulmonary disease and possibly
others without a de¢nite diagnostic label) and not just
the current asthmatic responders withwhosemorbidity
the ratios have been compared. Fourthly, some patients
withde¢nite current asthmamaybe‘deniers’as suggested
by qualitative research (5) and should properly have been
included in the current asthma group. This may restrict
the generalisabilityof theresultsbased on thosewith cur-
rent asthma.However, the number of practices surveyed
and the size of the data set gathered are likely to have
minimized anye¡ectof thesepoints on ourresultsFpar-
ticularly in terms of systematic bias.Lastly, the addition of
thewords ‘or coughing’ to the third question of the index
may have altered the validity of the instrument.
Little other research comparing outcomes of asthma
from across di¡erent practices exists, despite such a
needbeingrecognised (6).The ScottishGP academicNe-
ville et al. have shown that better care is associatedwith
having conducted a recent asthma audit (7) but this is
unlikely to be a useful repeatable measure. Corticoster-
oid/bronchodilator prescribing ratios (8,9), while popu-
lar, are at best process proxies for outcome and also
may be confounded by diagnostic label. Asthma mortal-
ity, admission rates to hospital, attendances at accident
and emergency departments and outpatient referrals,
while important and interesting markers at a district
wide level, are too low for individual practices to be use-
ful comparators of practice performance in asthma care.
The data presented in this study suggest that use of
the revised morbidity index in the manner described
could be such a useful comparator. It is simple, well re-
ceivedby doctors andpatients alike, robust and sensitive
to change (3). The current study shows that it picks up
variations between practices that go beyond age di¡er-
ences and use of inhaled steroids. The positive associa-
tion of the latter with high morbidity seems at ¢rst
sight to be counter-intuitive, but what it reveals is that
the mere use of inhaled steroids is insu⁄cient without
close andrepeated attention to diagnosis, choice of drug,
device, dose, inhaler technique and concordance with
prescriptions. These are components of quality care
which are likely to vary importantly between practices.
The postalmethod used in this study is helpful for set-
ting baselines, but this could be followed by annual op-
portunistic surveillance at routine contacts for other
purposes. These could not only be with doctors and
nurses but also with receptionists or pharmacists when
repeat prescriptions are being collected or dispensed.
Variations in the percentages of highmorbidity reported
by individual practices and year-on-year trends could be
used to identify models of cost-e¡ective asthma care
within and possibly between districts. In addition, prac-
tices in the upper or lower quartiles of high morbidity
could be examined more closely to seek potentially re-
mediable causes.The bene¢t to theNational Health Ser-vice of the approach taken in our study lies more in this
possibility than in the provision of precise data on asth-
ma prevalence or morbidity which could not have been
provided by our pragmatic methodology.
It is known that outcomes for patients with asthma in
the community can be improved by various care
initiatives (10^16) but it is less clear which parts of these
initiativesmake the biggest di¡erence (17,18).Widespread
use of the index or something similarly validated may
elucidate this issue further. The concept and utility of a
three-question asthma morbidity index has been recog-
nized and promoted by a nationalmeeting of asthma ex-
perts and enthusiasts (19). A revised version with
questions applicable to all those with asthma has been
proposed, but validation of the new wording has yet to
occur.
In conclusion, postal use of the revised Jones morbid-
ity index across practices identi¢es varying patterns of
morbidity which may be helpful in assessing the quality
of asthma care provided in the community.
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